<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2472">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04403243</url>
  </required_header>
  <id_info>
    <org_study_id>MSU080520</org_study_id>
    <nct_id>NCT04403243</nct_id>
  </id_info>
  <brief_title>COLchicine Versus Ruxolitinib and Secukinumab In Open Prospective Randomized Trial</brief_title>
  <acronym>COLORIT</acronym>
  <official_title>COLchicine Versus Ruxolitinib and Secukinumab In Open Prospective Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lomonosov Moscow State University Medical Research and Educational Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lomonosov Moscow State University Medical Research and Educational Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with mild and severe coronavirus disease 2019 (COVID 19) will be randomized 3:1:1:3
      into four groups: colchicine, ruxolitinib, secukinumab, and control groups. Patients will get
      investigated therapy for 10 days. Patients will be follow-up during 45 days after
      randomization. Change in clinical assessment score COVID 19 (CAS COVID 19) between baseline
      and 12th day will be evaluated as the primary endpoint. Risk of death or mechanical
      ventilation during 45 days after randomization will also be assessed
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 8, 2020</start_date>
  <completion_date type="Anticipated">August 23, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 22, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients will be randomized 3:1:1:3 into four groups: colchicine, ruxolitinib, secukinumab, and control group</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change from baseline in clinical assessment score COVID 19 (CAS COVID 19) Frame: baseline</measure>
    <time_frame>baseline, day 12</time_frame>
    <description>CAS COVID 19 measures clinical and laboratory parameters in 7 domains:
respiratory rate (&lt; 18 - 0 point; 18-22 - 1 point; 23-26 - 2 point; &gt;26 - 3 point)
body temperature (35.5 - 37.0 - 0 point; &lt; 35.5 - 1 point; 37.1 - 38.5 - 1 point; &gt; 38.5 - 2 point)
Sp02 without support oxygen (&gt; 93% - 0 point; 90-93% - 1 point; &lt; 90% - 2 point)
ventilation (not required - 0 point; low-flow ventilation - 1 point; Non-invasive positive pressure ventilation - 2 point; mechanical ventilation - 3 point)
C-reactive protein (&gt; 10 - 0 point; 10-59 - 1 point; 60-120 - 2 point; &gt; 120 - 3 point)
d - dimer (&lt; 0.51 - 0 point; 0.51 - 2.0 - 1 point; 2.01 - 5.0 - 2, &gt; 5.0 - 3 point)
exposure area on lung CT (no pneumonia - 0; 1-24% - 1 point; 25-50% - 2; 51-75% - 3, &gt; 75% - 4).
Minimal number of points - 0; max - 20. Lower the score-better health</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Combine endpoint: Time to death or mechanical ventilation</measure>
    <time_frame>45 days</time_frame>
    <description>time to death or mechanical ventilation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-reactive protein</measure>
    <time_frame>baseline, day 12, day 45</time_frame>
    <description>Change from baseline in C-reactive protein</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>D-dimer</measure>
    <time_frame>baseline, day 12, day 45</time_frame>
    <description>Change from baseline in D-dimer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EuroQol Group. EQ-5D™</measure>
    <time_frame>baseline, day 12, day 45</time_frame>
    <description>Change from baseline in EQ-5D-3L™ The EQ-5D-3L essentially consists of 2 pages: the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS).
The EQ-5D-3L descriptive system comprises the 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: no problems, some problems, and extreme problems. The patient is asked to indicate his/her health state by ticking the box to the most appropriate statement. This decision results into a 1-digit number, . The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state.
The EQ VAS records the patient's self-rated health on a vertical visual analogue scale where the endpoints are labelled 'Best imaginable health state' and 'Worst imaginable health state'. The VAS can be used as a quantitative measure of health outcome by patient's own judgement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>exposure area on lung CT</measure>
    <time_frame>baseline, day 12, day 45</time_frame>
    <description>Change from baseline in exposure area on lung CT</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>COVID 19</condition>
  <arm_group>
    <arm_group_label>1. Colchicine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30 Patients with mild and severe COVID 19 Patients will get investigated therapy for ten days. Patients will be follow-up during 45 days after randomization</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2. Ruxolitinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 Patients with mild and severe COVID 19 Patients will get investigated therapy for ten days. Patients will be follow-up during 45 days after randomization</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3.Secukinumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 Patients with mild and severe COVID 19 Patients will get investigated therapy for ten days. Patients will be follow-up during 45 days after randomization</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4.Standard treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>-30 patients Patients with mild and severe COVID 19 Patients will get investigated therapy for ten days. Patients will be follow-up during 45 days after randomization</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Colchicine</intervention_name>
    <description>0.5mg twice a day per os during the first three days and then 0.5mg daily per os if weight &lt; 86 kg or 0.5mg twice a day per os if weight &gt; 85kg for seven days.</description>
    <arm_group_label>1. Colchicine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ruxolitinib 5 MG</intervention_name>
    <description>Ruxolitinib - 5mg twice a day per os for ten days</description>
    <arm_group_label>2. Ruxolitinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Secukinumab 150 MG/ML Subcutaneous Solution [COSENTYX]</intervention_name>
    <description>Secukinumab - 300mg subcutaneously as the first dose and then 150mg twice a day subcutaneously for ten days</description>
    <arm_group_label>3.Secukinumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>standard therapy</intervention_name>
    <description>standard therapy for COVID 19</description>
    <arm_group_label>4.Standard treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed inform consent

          -  COVID 19 with the mild and severe course. The diagnosis could be made with positive
             polymerase chain reaction (PCR) (International Statistical Classification (ICD-10)
             code - U07.1) and/or virus pneumonia in computer tomography (ICD 10 code - U07.2)

          -  Lung exposure on CT more than 25%

          -  Sp02 without supportive oxygen ≤ 93%

          -  C-reactive protein &gt; 60 mg/l or elevation of C reactive protein 3 times in 8-14 days
             after first symptoms

        Exclusion Criteria:

          -  pregnancy and breastfeeding

          -  hypersensitivity to colchicine

          -  hypersensitivity to ruxolitinib

          -  hypersensitivity to secukinumab

          -  Known liver failure

          -  Glomerular filtration rate &lt;20 ml/ min

          -  physician judgment that the patient will need mechanical ventilation in 24 hours

          -  QTc &gt; 450 ms

          -  other indications for to colchicine, ruxolitinib, and secukinumab

          -  Chronic therapy with corticosteroids or immunosuppressive therapy

          -  Active cancer
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Julia Begrambekova, Phd</last_name>
    <phone>+79854679273</phone>
    <email>julia.begrambekova@ossn.ru</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yana Orlova, Professor</last_name>
    <phone>+79165163002</phone>
    <email>5163002@bk.ru</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Lomonosov Moscow State University Medical Research and Educational Center</name>
      <address>
        <city>Moscow</city>
        <state>Moscow Region</state>
        <zip>119620</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julia Leonovna Begrambekova, Phd</last_name>
      <phone>+79854679273</phone>
      <email>begrambekova@ossn.ru</email>
    </contact>
    <contact_backup>
      <last_name>Yana Orlova, Professor</last_name>
      <phone>+791651663002</phone>
      <email>yaorlova@mc.msu.ru</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 20, 2020</study_first_submitted>
  <study_first_submitted_qc>May 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 27, 2020</study_first_posted>
  <last_update_submitted>May 26, 2020</last_update_submitted>
  <last_update_submitted_qc>May 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID 19</keyword>
  <keyword>colchicine</keyword>
  <keyword>ruxolitinib</keyword>
  <keyword>secukinumab</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colchicine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>4 month</ipd_time_frame>
    <ipd_access_criteria>Medical professionals By the request</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

